{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:48:46Z","timestamp":1790686126614,"version":"4.1.0"},"reference-count":49,"publisher":"Akademiai Kiado Zrt.","issue":"13","license":[{"start":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T00:00:00Z","timestamp":1774742400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2026,3,29]]},"abstract":"Az autol\u00f3g haematopoeticus \u0151ssejt-transzplant\u00e1ci\u00f3 magyarorsz\u00e1gi alapjai az\n 1980-as \u00e9vek v\u00e9g\u00e9n kezdtek kibontakozni, m\u00e1ra m\u00e1r 6 hazai k\u00f6zpontban is a\n hematol\u00f3giai ter\u00e1pia rutinszer\u0171en alkalmazott r\u00e9sze. Az elj\u00e1r\u00e1s jelent\u0151s\n szerepet j\u00e1tszik a myeloma multiplex, a Hodgkin- \u00e9s non-Hodgkin-lymphom\u00e1k\n kezel\u00e9s\u00e9ben. Tov\u00e1bb\u00e1 a nem hematol\u00f3giai betegs\u00e9gek kezel\u00e9s\u00e9ben is egyre t\u00f6bb\n indik\u00e1ci\u00f3ja van. B\u00e1r az autol\u00f3g haematopoeticus \u0151ssejt-transzplant\u00e1ci\u00f3 az\n allog\u00e9n \u0151ssejt-transzplant\u00e1ci\u00f3n\u00e1l kevesebb akut sz\u00f6v\u0151dm\u00e9nnyel j\u00e1r, a ter\u00e1pia\n sor\u00e1n sz\u00e1mos r\u00f6vid \u00e9s hossz\u00fa t\u00e1v\u00fa cardiovascularis mell\u00e9khat\u00e1s fordulhat el\u0151,\n f\u0151k\u00e9nt a nagy d\u00f3zis\u00fa kemoter\u00e1pi\u00e1s el\u0151kezel\u00e9s \u00e9s az alapbetegs\u00e9g kezel\u00e9se kapcs\u00e1n\n a megel\u0151z\u0151en alkalmazott, potenci\u00e1lisan cardiotoxicus onkol\u00f3giai ter\u00e1pi\u00e1k\n k\u00f6vetkezt\u00e9ben. Mind az akut, a peritranszplant\u00e1ci\u00f3s id\u0151szak \u00e9s az azt k\u00f6vet\u0151 100\n nap alatt bek\u00f6vetkez\u0151, mind pedig a k\u00e9s\u0151i (\\>100 nap) cardiovascularis esem\u00e9nyek\n el\u0151fordul\u00e1sa jelent\u0151sen gyakoribb, mint a hasonl\u00f3 kor\u00fa \u00e1ltal\u00e1nos popul\u00e1ci\u00f3ban. A\n transzplant\u00e1ci\u00f3 sor\u00e1n fell\u00e9p\u0151 major adverz cardiovascularis esem\u00e9nyek\n limit\u00e1lhatj\u00e1k a ter\u00e1pia siker\u00e9t, valamint ronthatj\u00e1k a hematol\u00f3giai alapbetegs\u00e9g\n progn\u00f3zis\u00e1t \u00e9s a kezelt beteg \u00e9letmin\u0151s\u00e9g\u00e9t is. \u00c9ppen ez\u00e9rt ezek miel\u0151bbi\n felismer\u00e9se, el\u0151rejelz\u00e9se fontos, a primer \u00e9s szekunder prevenci\u00f3 alapj\u00e1t\n k\u00e9pezi, n\u00f6velve a betegek \u00e9letkil\u00e1t\u00e1sait \u00e9s \u00e9letmin\u0151s\u00e9g\u00e9t. K\u00f6zlem\u00e9ny\u00fcnk c\u00e9lja az\n autol\u00f3g haematopoeticus \u0151ssejt-transzplant\u00e1ci\u00f3 potenci\u00e1lis cardiovascularis\n mell\u00e9khat\u00e1sainak, ezek monitoroz\u00e1s\u00e1nak \u00e9s megfelel\u0151 ell\u00e1t\u00e1s\u00e1nak \u00f6sszefoglal\u00e1sa\n az aktu\u00e1lis nemzetk\u00f6zi hematol\u00f3giai \u00e9s onkokardiol\u00f3giai ir\u00e1nyelvek t\u00fckr\u00e9ben. Orv\n Hetil. 2026; 167(13): 490\u2013498.<\/jats:p>","DOI":"10.1556\/650.2026.33480","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T13:20:19Z","timestamp":1774876819000},"page":"490-498","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":1,"title":["Az autol\u00f3g \u0151ssejt-transzplant\u00e1ci\u00f3 kapcs\u00e1n fell\u00e9p\u0151 cardiovascularis sz\u00f6v\u0151dm\u00e9nyek"],"prefix":"10.1556","volume":"167","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2295-3106","authenticated-orcid":true,"given":"Zs\u00f3fia","family":"S\u00e1ndor","sequence":"first","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Hematol\u00f3giai Klinika Budapest Magyarorsz\u00e1g"},{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, V\u00e1rosmajori Sz\u00edv- \u00e9s \u00c9rgy\u00f3gy\u00e1szati Klinika Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Horv\u00e1th","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Hematol\u00f3giai Klinika Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"Masszi","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Hematol\u00f3giai Klinika Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zs\u00f3fia","family":"Drobni","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, V\u00e1rosmajori Sz\u00edv- \u00e9s \u00c9rgy\u00f3gy\u00e1szati Klinika Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"Pozsonyi","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Hematol\u00f3giai Klinika Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"425","reference":[{"key":"R1","doi-asserted-by":"crossref","unstructured":"Kelemen E, J\u00e1nossa M, Triska E, et al. Bone marrow transplantation\n in accelerated chronic granulocytic leukaemia using\n dibromomannitol\u2011preconditioning instead of total\u2011body irradiation. Leuk Res.\n 1985; 9: 1009-1015.\n https:\/\/doi.org\/10.1016\/0145-2126(85)90071-2","DOI":"10.1016\/0145-2126(85)90071-2"},{"key":"R2","doi-asserted-by":"crossref","unstructured":"Fekete S. Remembrance of the scientist, the physician and the\n teacher at the 2023 annual meeting of the Hungarian Society of Internal\n Medicine. [Dr. Kelemen Endre: Eml\u00e9kez\u00e9s a tud\u00f3sra, az orvosra \u00e9s a tan\u00e1rra a\n Magyar Belgy\u00f3gy\u00e1sz T\u00e1rsas\u00e1g 2023\u2011as nagygy\u0171l\u00e9s\u00e9n.] Magy Belorv Arch. 2024; 77:\n 284-287. [Hungarian]\n https:\/\/doi.org\/10.59063\/mba.2024.77.5-6.3","DOI":"10.59063\/mba.2024.77.5-6.3"},{"key":"R3","doi-asserted-by":"crossref","unstructured":"Granot N, Storb R. History of hematopoietic cell transplantation:\n challenges and progress. Haematologica 2020; 105: 2716-2729.\n https:\/\/doi.org\/10.3324\/haematol.2019.245688","DOI":"10.3324\/haematol.2019.245688"},{"key":"R4","unstructured":"Semmelweis University announces availability of stem cell\n transplantation. [M\u00e1r a Semmelweis Egyetemen is el\u00e9rhet\u0151 az\n \u0151ssejt-transzplant\u00e1ci\u00f3.] Available from:\n hhttps:\/\/semmelweis.hu\/hirek\/2024\/12\/11\/mar-a-semmelweis-egyetemen-is-elerheto-az-ossejt-transzplantacio\/\n [accessed: Nov 13, 2025]. [Hungarian]"},{"key":"R5","doi-asserted-by":"crossref","unstructured":"Sharma SK. Indications for autologous stem cell transplant. In:\n Sharma SK (ed.) Basics of hematopoietic stem cell transplant. Springer Nature,\n Singapore, 2023; pp. 239-245.\n https:\/\/doi.org\/10.1007\/978-981-19-5802-1_20","DOI":"10.1007\/978-981-19-5802-1_20"},{"key":"R6","doi-asserted-by":"crossref","unstructured":"Al Hamed R, Bazarbachi AH, Malard F, et al. Current status of\n autologous stem cell transplantation for multiple myeloma. Blood Cancer J. 2019;\n 9: 44-44. https:\/\/doi.org\/10.1038\/s41408-019-0205-9","DOI":"10.1038\/s41408-019-0205-9"},{"key":"R7","doi-asserted-by":"crossref","unstructured":"T\u00f3th T, Alizadeh H. On the threshold of a possible cure: innovations\n in treating multiple myeloma. [Az el\u00e9rhet\u0151 gy\u00f3gyul\u00e1s k\u00fcsz\u00f6b\u00e9n: innov\u00e1ci\u00f3k a\n myeloma multiplex kezel\u00e9s\u00e9ben.] Orv Hetil. 2024; 165: 891-899. [Hungarian]\n https:\/\/doi.org\/10.1556\/650.2024.33036","DOI":"10.1556\/650.2024.33036"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"Serrano\u2011Fernandez V, Carmona\u2011Torres JM, Arroyo\u2011Rodriguez A, et al.\n Hematopoietic stem cell transplantation therapy for refractory Crohn disease: a\n systematic review and meta\u2011analysis. Medicine (Baltimore) 2024; 103: e40144.\n https:\/\/doi.org\/10.1097\/MD.0000000000040144","DOI":"10.1097\/MD.0000000000040144"},{"key":"R9","doi-asserted-by":"crossref","unstructured":"McCaughan G, Beer H, Bryant C, et al. Management of patients with\n newly diagnosed multiple myeloma who are eligible for autologous stem cell\n transplantation: position statement of the Medical and Scientific Advisory Group\n of Myeloma Australia. Intern Med J. 2025; 55: 1741-1751.\n https:\/\/doi.org\/10.1111\/imj.70148","DOI":"10.1111\/imj.70148"},{"key":"R10","doi-asserted-by":"crossref","unstructured":"Mohananey D, Sarau A, Kumar R, et al. Role of physical activity and\n cardiac rehabilitation in patients undergoing hematopoietic stem cell\n transplantation. JACC CardioOncol. 2021; 3: 17-34.\n https:\/\/doi.org\/10.1016\/j.jaccao.2021.01.008","DOI":"10.1016\/j.jaccao.2021.01.008"},{"key":"R11","doi-asserted-by":"crossref","unstructured":"Ruff E, Ga\u00e1l L, Szita VR, et al. Survival outcomes of patients with\n multiple myeloma treated at the Department of Internal Medicine and Hematology,\n Semmelweis University. [Myeloma multiplexben szenved\u0151 betegek t\u00fal\u00e9l\u00e9si\n eredm\u00e9nyei a Semmelweis Egyetem Belgy\u00f3gy\u00e1szati \u00e9s Hematol\u00f3giai Klinik\u00e1j\u00e1n.] Orv\n Hetil. 2024; 165: 1539-1547. [Hungarian]\n https:\/\/doi.org\/10.1556\/650.2024.33120","DOI":"10.1556\/650.2024.33120"},{"key":"R12","doi-asserted-by":"crossref","unstructured":"Buda G, Del Giudice ML, Antonioli E, et al. Real\u2011life experience\n with first-line therapy bortezomib plus melphalan and prednisone in elderly\n patients with newly diagnosed multiple myeloma ineligible for high\u2011dose\n chemotherapy with autologous stem\u2011cell transplantation. Front Med (Lausanne)\n 2021; 8: 712070.\n https:\/\/doi.org\/10.3389\/fmed.2021.712070","DOI":"10.3389\/fmed.2021.712070"},{"key":"R13","doi-asserted-by":"crossref","unstructured":"Gent DG, Saif M, Dobson R, et al. Cardiovascular disease after\n hematopoietic stem cell transplantation in adults: JACC CardioOncology\n State\u2011of\u2011the\u2011Art review. JACC CardioOncol. 2024; 6: 475-495.\n https:\/\/doi.org\/10.1016\/j.jaccao.2024.06.004","DOI":"10.1016\/j.jaccao.2024.06.004"},{"key":"R14","doi-asserted-by":"crossref","unstructured":"Hayek SS, Zaha VG, Bogle C, et al. Cardiovascular management of\n patients undergoing hematopoietic stem cell transplantation: from\n pretransplantation to survivorship: a scientific statement from the American\n Heart Association. Circulation 2024; 149: e1113-e1127.\n https:\/\/doi.org\/10.1161\/CIR.0000000000001220","DOI":"10.1161\/CIR.0000000000001220"},{"key":"R15","doi-asserted-by":"crossref","unstructured":"Vasbinder A, Hoeger CW, Catalan T, et al. Cardiovascular events\n after hematopoietic stem cell transplant: incidence and risk factors. JACC\n CardioOncol. 2023; 5: 821-832.\n https:\/\/doi.org\/10.1016\/j.jaccao.2023.07.007","DOI":"10.1016\/j.jaccao.2023.07.007"},{"key":"R16","doi-asserted-by":"crossref","unstructured":"Auberle C, Lenihan D, Gao F, et al. Late cardiac events after\n allogeneic stem cell transplant: incidence, risk factors, and impact on overall\n survival. Cardiooncology 2023; 9: 1.\n https:\/\/doi.org\/10.1186\/s40959-022-00150-1","DOI":"10.1186\/s40959-022-00150-1"},{"key":"R17","unstructured":"Vasbinder A, Catalan T, Anderson E, et al. Cardiovascular risk\n stratification of patients undergoing hematopoietic stem cell transplantation:\n the CARE\u2011BMT risk score. J Am Heart Assoc. 2024; 13: e033599."},{"key":"R18","doi-asserted-by":"crossref","unstructured":"Camilli M, Maggio L, Tinti L, et al. Cardio\u2011oncology: emerging\n concepts in cardiovascular sequelae of cancer therapies, translational research\n and reverse cardio\u2011oncology. Eur Cardiol. 2025; 20: e05.\n https:\/\/doi.org\/10.15420\/ecr.2024.49","DOI":"10.15420\/ecr.2024.49"},{"key":"R19","doi-asserted-by":"crossref","unstructured":"Spannbauer A, Bergler\u2011Klein J. Cardio\u2011Oncology: a new discipline in\n medicine and its relevance to hematology. Haemostaseologie 2024; 44: 255-267.\n https:\/\/doi.org\/10.1055\/a-2284-5855","DOI":"10.1055\/a-2284-5855"},{"key":"R20","doi-asserted-by":"crossref","unstructured":"Meijers WC, Maglione M, Bakker SJ, et al. Heart failure stimulates\n tumor growth by circulating factors. Circulation 2018; 138: 678-691.\n https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.030816","DOI":"10.1161\/CIRCULATIONAHA.117.030816"},{"key":"R21","doi-asserted-by":"crossref","unstructured":"Sayour NV, Pa\u00e1l \u00c1M, Ameri P, et al. Heart failure pharmacotherapy\n and cancer: pathways and pre\u2011clinical\/clinical evidence. Eur Heart J. 2024; 45:\n 1224-1240. https:\/\/doi.org\/10.1093\/eurheartj\/ehae105","DOI":"10.1093\/eurheartj\/ehae105"},{"key":"R22","doi-asserted-by":"crossref","unstructured":"Bloom MW, Vo JB, Rodgers JE, et al. Cardio\u2011oncology and heart\n failure: a scientific statement from the Heart Failure Society of America. J\n Card Fail. 2025; 31: 415-455.\n https:\/\/doi.org\/10.1016\/j.cardfail.2024.08.045","DOI":"10.1016\/j.cardfail.2024.08.045"},{"key":"R23","doi-asserted-by":"crossref","unstructured":"Jaiswal S, Ebert BL. Clonal hematopoiesis in human aging and\n disease. Science 2019; 366: eaan4673.\n https:\/\/doi.org\/10.1126\/science.aan4673","DOI":"10.1126\/science.aan4673"},{"key":"R24","doi-asserted-by":"crossref","unstructured":"Jaiswal S, Fontanillas P, Flannick J, et al. Age\u2011related clonal\n hematopoiesis associated with adverse outcomes. N Engl J Med. 2014; 371:\n 2488-2498. https:\/\/doi.org\/10.1056\/NEJMoa1408617","DOI":"10.1056\/NEJMoa1408617"},{"key":"R25","doi-asserted-by":"crossref","unstructured":"Ezzat D, Uddin MM, Xue L, et al. Clonal hematopoiesis and\n cardiovascular outcomes in older women. J Am Coll Cardiol. 2025; 86: 1093-1106.\n https:\/\/doi.org\/10.1016\/j.jacc.2025.07.058","DOI":"10.1016\/j.jacc.2025.07.058"},{"key":"R26","doi-asserted-by":"crossref","unstructured":"Gumuser ED, Schuermans A, Cho SM, et al. Clonal hematopoiesis of\n indeterminate potential predicts adverse outcomes in patients with\n atherosclerotic cardiovascular disease. J Am Coll Cardiol. 2023; 81: 1996-2009.\n https:\/\/doi.org\/10.1016\/j.jacc.2023.03.401","DOI":"10.1016\/j.jacc.2023.03.401"},{"key":"R27","doi-asserted-by":"crossref","unstructured":"Testa U, Castelli G, Pelosi E. Clonal hematopoiesis, a risk\n condition for developing myeloid neoplasia. Hemato 2025; 6: 10.\n https:\/\/doi.org\/10.3390\/hemato6020010","DOI":"10.3390\/hemato6020010"},{"key":"R28","doi-asserted-by":"crossref","unstructured":"Singh J, Li N, Ashrafi E, et al. Clonal hematopoiesis of\n indeterminate potential as a prognostic factor: a systematic review and\n meta\u2011analysis. Blood Adv. 2024; 8: 3771-3784.\n https:\/\/doi.org\/10.1182\/bloodadvances.2024013228","DOI":"10.1182\/bloodadvances.2024013228"},{"key":"R29","doi-asserted-by":"crossref","unstructured":"Awada H, Gurnari C, Visconte V, et al. Clonal hematopoiesis\u2011derived\n therapy-related myeloid neoplasms after autologous hematopoietic stem cell\n transplant for lymphoid and non\u2011lymphoid disorders. Leukemia 2024; 38:\n 1266-1274.\n https:\/\/doi.org\/10.1038\/s41375-024-02258-y","DOI":"10.1038\/s41375-024-02258-y"},{"key":"R30","doi-asserted-by":"crossref","unstructured":"Gibson CJ, Lindsley RC, Tchekmedyian V, et al. Clonal hematopoiesis\n associated with adverse outcomes after autologous stem\u2011cell transplantation for\n lymphoma. J Clin Oncol. 2017; 35: 1598-1605.\n https:\/\/doi.org\/10.1200\/JCO.2016.71.6712","DOI":"10.1200\/JCO.2016.71.6712"},{"key":"R31","doi-asserted-by":"crossref","unstructured":"Yan C, Richard MA, Gibson CJ, et al. Clonal hematopoiesis and\n therapy-related myeloid neoplasms after autologous transplant for Hodgkin\n lymphoma. J Clin Oncol. 2024; 42: 2415-2424.\n https:\/\/doi.org\/10.1200\/JCO.23.02547","DOI":"10.1200\/JCO.23.02547"},{"key":"R32","doi-asserted-by":"crossref","unstructured":"Mangaonkar AA, Bolton KL, Patnaik MM. Clonal hematopoiesis of\n indeterminate potential and clonal cytopenias of undetermined significance: 2026\n update on clinical associations and management recommendations. Am J Hematol.\n 2026; 101: 550-565.\n https:\/\/doi.org\/10.1002\/ajh.70205","DOI":"10.1002\/ajh.70205"},{"key":"R33","doi-asserted-by":"crossref","unstructured":"Aghel N, Lui M, Wang V, et al. Cardiovascular events among\n recipients of hematopoietic stem cell transplantation: a systematic review and\n meta\u2011analysis. Bone Marrow Transplant. 2023; 58: 478-490.\n https:\/\/doi.org\/10.1038\/s41409-023-01928-2","DOI":"10.1038\/s41409-023-01928-2"},{"key":"R34","doi-asserted-by":"crossref","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, et al. 2022 ESC guidelines on\n cardio-oncology developed in collaboration with the European Hematology\n Association (EHA), the European Society for Therapeutic Radiology and Oncology\n (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J.\n 2022; 43: 4229-4361. Erratum: Eur Heart J. 2023; 44: 1621.\n https:\/\/doi.org\/10.1093\/eurheartj\/ehad196","DOI":"10.1093\/eurheartj\/ehad196"},{"key":"R35","doi-asserted-by":"crossref","unstructured":"Chiengthong K, Lertjitbanjong P, Thongprayoon C, et al. Arrhythmias\n in hematopoietic stem cell transplantation: a systematic review and\n meta\u2011analysis. Eur J Haematol. 2019; 103: 564-572.\n https:\/\/doi.org\/10.1111\/ejh.13322","DOI":"10.1111\/ejh.13322"},{"key":"R36","doi-asserted-by":"crossref","unstructured":"Rim A, Graiser M, Mandawat A. Incidence and risk factors for atrial\n fibrillation and atrial flutter in patients with multiple myeloma after\n melphalan conditioning for autologous stem cell transplant. J Am Coll Cardiol.\n 2021; 77(18_Suppl 1): 3276.\n https:\/\/doi.org\/10.1016\/S0735-1097(21)04630-1","DOI":"10.1016\/S0735-1097(21)04630-1"},{"key":"R37","doi-asserted-by":"crossref","unstructured":"Aghel N, Wang V, Leong D, et al. Early cardiovascular events in\n recipients of allogeneic hematopoietic stem cell transplantation. JACC Advances\n 2025; 4: 101760.\n https:\/\/doi.org\/10.1016\/j.jacadv.2025.101760","DOI":"10.1016\/j.jacadv.2025.101760"},{"key":"R38","doi-asserted-by":"crossref","unstructured":"Deveci B, Ate\u015fo\u011flu EB, Bayrak E, et al. Comparative efficacy and\n safety of BEAM and TEAM conditioning regimens for autologous stem cell\n transplantation in lymphoma patients. Transplant Proc. 2023; 55: 235-241.\n https:\/\/doi.org\/10.1016\/j.transproceed.2022.12.001","DOI":"10.1016\/j.transproceed.2022.12.001"},{"key":"R39","doi-asserted-by":"crossref","unstructured":"Srour SA, Milton DR, Bashir Q, et al. Melphalan dose intensity for\n autologous stem cell transplantation in multiple myeloma. Haematologica 2021;\n 106: 3211-3214.\n https:\/\/doi.org\/10.3324\/haematol.2021.279179","DOI":"10.3324\/haematol.2021.279179"},{"key":"R40","doi-asserted-by":"crossref","unstructured":"Ghani DA, Iftikhar R, Bokhari SWI, et al. Finding the sweet spot:\n melphalan dosing for autologous hematopoietic stem cell transplant for multiple\n myeloma in challenging environments. Blood 2024; 144: 7048.\n https:\/\/doi.org\/10.1182\/blood-2024-210421","DOI":"10.1182\/blood-2024-210421"},{"key":"R41","doi-asserted-by":"crossref","unstructured":"Rotz SJ, Bhatt NS, Hamilton BK, et al. International recommendations\n for screening and preventative practices for long-term survivors of\n transplantation and cellular therapy: a 2023 update. Transpl Cell Ther. 2024;\n 30: 349-385.\n https:\/\/doi.org\/10.1016\/j.jtct.2023.12.001","DOI":"10.1016\/j.jtct.2023.12.001"},{"key":"R42","doi-asserted-by":"crossref","unstructured":"Majhail NS. How to perform hematopoietic stem cell transplantation.\n J Am Coll Cardiol CardioOnc. 2021; 3: 742-746.\n https:\/\/doi.org\/10.1016\/j.jaccao.2021.09.012","DOI":"10.1016\/j.jaccao.2021.09.012"},{"key":"R43","doi-asserted-by":"crossref","unstructured":"Vaitiekiene A, Kulboke M, Bieseviciene M, et al. Evaluation of\n subclinical cancer therapy-related cardiac dysfunction in patients undergoing\n hematopoietic stem cell transplantation: an echocardiography study. Cancers\n (Basel) 2024; 16: 3808.\n https:\/\/doi.org\/10.3390\/cancers16223808","DOI":"10.3390\/cancers16223808"},{"key":"R44","doi-asserted-by":"crossref","unstructured":"McErlean G, Ashley C, Pradhan A, et al. A qualitative study on blood\n and marrow transplant recipients\u2019 perceptions of health professional roles\n following BMT and preferences for ongoing care. J Cancer Surviv. 2024; Aug 17.\n https:\/\/doi.org\/10.1007\/s11764-024-01658-4","DOI":"10.1007\/s11764-024-01658-4"},{"key":"R45","doi-asserted-by":"crossref","unstructured":"Czuriga D, Drobni Zs, Pozsonyi Z. Evolution of defining and\n reinterpretation of cardiotoxicity. [A kardiotoxicit\u00e1s defin\u00edci\u00f3j\u00e1nak evol\u00faci\u00f3ja\n \u00e9s \u00fajra\u00e9rtelmez\u00e9se.] Cardiol Hung. 2023; 53: 89-94. [Hungarian]\n https:\/\/doi.org\/10.26430\/CHUNGARICA.2023.53.2.89","DOI":"10.26430\/CHUNGARICA.2023.53.2.89"},{"key":"R46","doi-asserted-by":"crossref","unstructured":"Massey RJ, Diep PP, Ruud E, et al. Left ventricular systolic\n function in long-term survivors of allogeneic hematopoietic stem cell\n transplantation. JACC CardioOncol. 2020; 2: 460-471.\n https:\/\/doi.org\/10.1016\/j.jaccao.2020.06.011","DOI":"10.1016\/j.jaccao.2020.06.011"},{"key":"R47","doi-asserted-by":"crossref","unstructured":"S\u00e1ndor Zs, Proh\u00e1szka B, Gr\u00e1f L, et al. Focused summary of the 2022\n ESC cardio\u2011oncology guidelines. [F\u00f3kusz\u00e1lt \u00f6sszefoglal\u00f3 az ESC 2022\u2011es\n onko\u2011kardiol\u00f3giai ir\u00e1nyelv\u00e9r\u0151l.] Cardiol Hung. 2023; 53: 78-88. [Hungarian]\n https:\/\/doi.org\/10.26430\/CHUNGARICA.2023.53.2.78","DOI":"10.26430\/CHUNGARICA.2023.53.2.78"},{"key":"R48","doi-asserted-by":"crossref","unstructured":"Yang C, Khan F, MacDonald C, et al. Characterization of direct oral\n anticoagulants use in adult hematopoietic stem cell transplant recipients. J\n Thromb Thrombolysis 2024; 57: 293-301.\n https:\/\/doi.org\/10.1007\/s11239-023-02902-x","DOI":"10.1007\/s11239-023-02902-x"},{"key":"R49","doi-asserted-by":"crossref","unstructured":"Livneh N, Braeken D, Drozdinsky G, et al. Anticoagulation in\n patients with atrial fibrillation, thrombocytopenia and hematological\n malignancy. J Thromb Thrombolysis 2021; 52: 590-596.\n https:\/\/doi.org\/10.1007\/s11239-021-02393-8","DOI":"10.1007\/s11239-021-02393-8"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/167\/13\/article-p490.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/167\/13\/article-p490.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/167\/13\/article-p490.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T13:20:37Z","timestamp":1774876837000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/167\/13\/article-p490.xml"}},"subtitle":["Aktualit\u00e1sok az onkokardiol\u00f3gia t\u00fckr\u00e9ben"],"short-title":[],"issued":{"date-parts":[[2026,3,29]]},"references-count":49,"journal-issue":{"issue":"13"},"URL":"https:\/\/doi.org\/10.1556\/650.2026.33480","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,29]]}}}